PDCD1 and neoplasm: Similarly, a study by Germano et al. reported a decrease in immunosuppressive factors such as MDSCs and tumor- associated macrophages (TAMs) from in vivo combinatorial treatment with trabectedin and anti-PD-1 therapy [68].